传奇故事

一 |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。1月15日，Redmi Red Rice Note7在今天上午10点首次售出。黑色版999/1399元，全彩1199元，40分钟后仍可购买。对小米来说，开放第一次销售的现货供应是非常困难的。

二 | 48米后双全血版茂龙660预计将从1月22日至23日发货：在这里购买。小费这个红色信封，可以叠加任何折扣。红米红米注7、3、32GB为999元，4、64GB为1199元，6、64GB为1399元。Redmi Red Rice Note7使用6.3英寸的全屏幕水滴，双面康宁大猩猩第五代玻璃。

三 | 它配备了Paragon 660处理器的“全血版”。否则，红米注7标准C型接口，还保留了3.5毫米耳机孔，红外遥控。本机还采用DSM动态增益控制和定制AAC微型扬声器。

四 | 外部放大的体积增加了2.5倍。设计了0.64cc独立音箱扬声器。响度大，音效好，质量保证18个月。京东红饭注7 3GB 32GB999元直销京东红饭注7 4GB 64GB 1199元直销京东手机春节特产：指向全品类的京西红包提供，0:00打开红包：指向此红包。